Video

Dr. Epperla Discusses the Current Treatment of MCL

Author(s):

Narendranath Epperla, MBBS, MS

In Partnership With:

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma.

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma (MCL).

Upfront treatment for MCL continues to be induction therapy followed by autologous stem cell transplant, says Epperla. This is based on the long term follow-up data from the NORDIC trial.

In the relapsed/refractory setting, there are many agents to choose from—BTK inhibitors, PI3-kinase inhibitors, and immunomodulatory agents. Epperla says these agents can be used in various combinations.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
January 6th 2025

ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

Alice Mims, MD, medical oncologist, associate professor, the Division of Hematology, The Ohio State University Comprehensive Cancer Center—James
February 26th 2024

Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

Matthew Lunning, DO, FACP
January 22nd 2024

Lunning and Maddocks Talk Through Frontline MCL Management

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma

Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma